Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;123(6):1432-1440.
doi: 10.1002/jso.26384.

Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma

Zachary J Brown  1 , Jordan M Cloyd  1
Affiliations
Review

Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma

Zachary J Brown et al. J Surg Oncol. 2021 May.

Abstract

For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection. Three decades of refining the use of NT have led to its acceptance as a valid treatment approach for pancreatic adenocarcinoma. In this review, we discuss the rationale for and recent global trends in the utilization of NT for patients with pancreatic cancer.

Keywords: FOLFIRINOX; neoadjuvant chemotherapy; pancreatic cancer; pancreatoduodenectomy; preoperative therapy; whipple.

PubMed Disclaimer

References

REFERENCES

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
    1. Cloyd JM, Katz MHG, Prakash L, et al. Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastrointestinal Surg. 2017;21(1):164-174.
    1. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
    1. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-1481.
    1. Cloyd JM, Shen C, Santry H, et al. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. J Natl Comprehensive Cancer Network: JNCCN. 2020;18(5):556-563.

MeSH terms

LinkOut - more resources